CD274 and gastrointestinal stromal tumor: Nevertheless, a preclinical study on mouse models of GIST showed that the therapeutic efficacy of imatinib can be increased by combining this TKI with immune checkpoint inhibitors targeting PD-1/PD-L1 [38].